Reconstruction of an arteriovenous graft using the transected end of a pre-existing stent graft: A case report.

J Vasc AccessMay 4, 2026 (epub)
Case ReportVascular Surgery

Takehisa Nojima, Yasuki Motomiya, Kanako Takai

✦ AI-curated · Sources linked

Case in brief

A 78-year-old woman on long-term hemodialysis experienced graft degeneration with recurrent stenosis despite having a functioning stent graft. Due to the infeasibility of creating new vascular access, ipsilateral reconstruction was performed. A new prosthetic graft was anastomosed to the radial artery, and the transected end of the stent graft was used for venous anastomosis. Postoperative angiography showed good patency, and the AVG was ready for cannulation in 10 days.

Diagnostic / clinical pearl

This case illustrates the potential for reusing a transected stent graft in arteriovenous graft reconstruction, which may be a viable option in select patients with graft degeneration.

Source

PubMed · PMID 42077113

Published in J Vasc Access. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Vascular Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.